{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.5","upperLimit":"18.1","value":"13.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Overall survival will be defined as the time from registration to death. Patients lost to follow-up for this endpoint will be censored at the date of last contact (i.e., last known alive). The distribution of overall survival will be estimated using Kaplan-Meier methodology.","dispersionType":"95% Confidence Interval","groups":[{"description":"Group 1 (6/6 UGT1A1 genotype):\\> Patients receive 150 mg/m\\^2 irinotecan hydrochloride IV over 90 minutes and 100 mg/m\\^2 oxaliplatin IV over 2 hours on day 1. Patients also receive 1600 mg/m\\^2/day capecitabine PO BID on days 2-15\\> \\> Group 2 (6/7 UGT1A1 genotype):\\> Patients receive 150 mg/m\\^2 irinotecan hydrochloride IV over 90 minutes and 85 mg/m\\^2 oxaliplatin IV over 2 hours on day 1. Patients also receive 400 mg/m\\^2/day capecitabine PO BID on days 2-15.\\>\n\n\\> Group 3 (7/7 UGT1A1 genotype):\\> Patients receive 75 mg/m\\^2 irinotecan hydrochloride IV over 90 minutes and 85 mg/m\\^2 oxaliplatin IV over 2 hours on day 1. Patients also receive 400 mg/m\\^2/day capecitabine PO BID on days 2-15","id":"OG000","title":"All Patients (6/6, 6/7, 7/7 UGT1A1 Genotype)"}],"paramType":"MEDIAN","populationDescription":"One patient was later found to be a major treatment violation during cycle 1 and was not included in this analysis. All the other 32 patients were analyzed together for this endpoint.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}